Skip to navigation Skip to content



About this Medication
  • Brand Name: Tyruko® (tie-ROO-koh) (natalizuman-sztn, biosimilar to Tysabri)
  • Chemical Name: natalizumab-sztn (na-ta-lie-zoo-mab-sztn)
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No

This medication is given by IV infusion.


Tyruko® is biosimilar to Tysabri®. It is a laboratory-produced monoclonal antibody. It is designed to hamper movement of potentially damaging immune cells from the bloodstream, across the “blood-brain barrier” into the brain and spinal cord.

Tyruko is approved by the U.S. Food and Drug Administration (FDA) as a monotherapy (not to be used in combination with other disease-modifying therapies) for the treatment of relapsing forms of multiple sclerosis, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses).

Click here to read the Tysabri Prescribing Information and Medication Guide.



Financial Assistance Program

No patient assistance program available at this time.

Infusion Center Resources

National Infusion Center Association - non-profit patient advocacy organization which offers an online Infusion Center Finder to locate centers throughout the U.S. that administer IV/injectable medications. NICA also provides online consumer education to help patients learn more about infusion services.


© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.